(ABCL) Abcellera Biologics - Performance 25.3% in 12m
ABCL performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-78.17%
#127 in Peer-Group
Rel. Strength
75.59%
#1871 in Stock-Universe
Total Return 12m
25.31%
#33 in Peer-Group
Total Return 5y
-93.19%
#138 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | 27.5 |
| High / Low | USD |
|---|---|
| 52 Week High | 4.25 USD |
| 52 Week Low | 1.93 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 91.74 |
| Buy/Sell Signal +-5 | -2.01 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: ABCL (25.3%) vs XBI (-12.9%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
-0.31% | 59.8% | 74.7% | 24.1 | 14.3 | 0.24 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
4.3% | -9.7% | 155% | 12 | 11 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
0.02% | -7.68% | 38% | 27.4 | 14.2 | 0.99 | 0.60% | 41% |
| BIM PA Biomerieux |
-1.08% | 26.2% | -2.56% | 32.7 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
7.29% | -9.49% | 5.85% | 45.7 | 26.2 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.7% | 37.9% | -6.21% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-5.29% | 46.5% | -8.05% | 7.54 | 6.09 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
0.46% | 28.5% | 19% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: ABCL vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for ABCL
| Total Return (including Dividends) | ABCL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 25.31% | 4.10% | 4.77% |
| 3 Months | 64.34% | 13.70% | 16.02% |
| 12 Months | 25.31% | -12.86% | 12.44% |
| 5 Years | -93.19% | -21.96% | 112.73% |
| Trend Score (consistency of price movement) | ABCL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 90.3% | 52.1% | 90.3% |
| 3 Months | 60% | 79.4% | 97.5% |
| 12 Months | -13% | -87.4% | 46.4% |
| 5 Years | -95.9% | -52.1% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th89.00 | 20.38% | 19.61% |
| 3 Month | %th85.00 | 44.54% | 41.65% |
| 12 Month | %th83.50 | 43.81% | 11.45% |
| 5 Years | %th37.50 | -88.91% | -96.26% |
FAQs
Does Abcellera Biologics (ABCL) outperform the market?
Yes,
over the last 12 months ABCL made 25.31%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.86%.
Over the last 3 months ABCL made 64.34%, while XBI made 13.70%.
Performance Comparison ABCL vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
ABCL vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -1% | 20.5% | 25.8% | 13% |
| US NASDAQ 100 | QQQ | -0.9% | 20% | 23.8% | 13% |
| German DAX 40 | DAX | -1.3% | 22.2% | 13.7% | -4% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.2% | 20.2% | 21.3% | 6% |
| Hongkong Hang Seng | HSI | -1.9% | 21.4% | 3.8% | -9% |
| India NIFTY 50 | INDA | 0.4% | 23.8% | 25.3% | 29% |
| Brasil Bovespa | EWZ | 3.2% | 25.7% | 10.7% | 25% |
ABCL vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 0.4% | 21.7% | 22.5% | 2% |
| Consumer Discretionary | XLY | -1.9% | 20.5% | 33.5% | 9% |
| Consumer Staples | XLP | 1.1% | 24.8% | 26.7% | 18% |
| Energy | XLE | -3.9% | 23.3% | 33.3% | 25% |
| Financial | XLF | 0.5% | 20.6% | 23.5% | 2% |
| Health Care | XLV | -1.1% | 25.5% | 37.3% | 32% |
| Industrial | XLI | -1.4% | 19.7% | 19.9% | 3% |
| Materials | XLB | -1.6% | 20% | 25.1% | 22% |
| Real Estate | XLRE | -0.7% | 25.2% | 27.3% | 18% |
| Technology | XLK | -0.9% | 18.2% | 20.7% | 15% |
| Utilities | XLU | -1% | 23.3% | 21.7% | 3% |
| Aerospace & Defense | XAR | -1.6% | 18.1% | 5.8% | -22% |
| Biotech | XBI | -4.6% | 21.2% | 36% | 38% |
| Homebuilder | XHB | -4% | 14% | 32.4% | 28% |
| Retail | XRT | -0.9% | 18.5% | 30.6% | 19% |
ABCL vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -1.6% | 29.0% | 39.7% | 29% |
| Natural Gas | UNG | 0.8% | 34.1% | 51.8% | 22% |
| Gold | GLD | -1.1% | 27.6% | 7.9% | -13% |
| Silver | SLV | -5.3% | 19.1% | 3.7% | 0% |
| Copper | CPER | -11.3% | 9.4% | 6.2% | 2% |
ABCL vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -0.1% | 25.6% | 31.1% | 29% |
| iShares High Yield Corp. Bond | HYG | -0.4% | 24% | 28.8% | 17% |